The identification of variants in IL6ST, IL6R, REL, and TNFAIP3 in our cohort further supports the contribution of the IL-6 signalling pathway to disease activity and fibrotic progression in SSc. This evidence concerns the gene TNFAIP3 and systemic sclerosis.